Allergen-Specific Immunotherapy Market: Opportunity Analysis and Forecast to 2018

"The Report OpportunityAnalyzer: Allergic Rhinitis: Allergen-Specific Immunotherapy - Opportunity Analysis and Forecast to 2018 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

About Allergen-Specific Immunotherapy Market

The global specific immunotherapy (SIT) market for allergic rhinitis (AR) is highly fragmented, with the US, Europe, and Japan having different SIT formulations available, under different regulatory restrictions, with almost no historical company crossover between markets. Europe has the most developed market, with subcutaneous immunotherapy (SCIT), sublingual immunotherapy (SLIT), and allergen immunotherapy tablets (AITs) all being available. However, economy-driven healthcare expenditure restrictions have led to negative growth in European SIT sales for many companies, and in addition new German regulatory guidelines means now previously European-centric allergen extract manufacturers are partnering with US and Japanese pharmaceutical companies to distribute their therapies in the previously underdeveloped markets. In the US, the introduction of AITs will drive growth in the AR immunotherapies market, due to their high cost relative to standard subcutaneous allergen extracts. The total allergen extract immunotherapy market is expected to grow from $172.5m to $688.3m between 2013 and 2018. Japan, a market previously not widely treated with SIT, is set to see a new range of standardized, clinically-evaluated products containing the two most prevalent allergens, house dust mite (HDM) and Japanese cedar pollen. Available options will include AIT formulations previously unavailable in the market. GlobalData projects that the immunotherapy sales in Japan will reach $47.09m in 2018, with a CAGR of 70.24%.

Highlights

Get Sample Copy of this report @ https://www.marketresearchreports.biz/sample/sample/235081

Key Questions Answered

- Although SIT is the only therapy that targets the cause of AR, the drug treatment rate is low. The AR SIT market is still marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? What are the R&D approaches currently being explored?
- How will the requirement for SIT registration in Germany impact the AR SIT market in the 5MM? How will this process impact the market leaders in this space? Which of these companies will attain high sales revenues during 2013-2018? Which company will have the highest peak sales at the highest CAGR, and why?
- The current AR SIT market in the US and Japan is dominated by SCIT. How will the advent of allergen immunotherapy tablets change the drug treatment landscape for AR in these markets? How will the drug treatment rate change over the next five years? What are the key drivers and barriers to this change?

Key Findings

- A major driver to the US market will be the introduction of several allergen immunotherapy tablets (AITs): Mercks Grastek (grass), Ragwitek (ragweed), and Mitizax (HDM) tablets, as well as Greers Oralair (grass). These new products overcome the inconvenience of conventional subcutaneous immunotherapies (SCIT). the higher profit margins associated with AIT compared with SCIT will boost the US market size, even if uptake is minimal.
- The main driver to an increase in the drug treatment rate and the expansion of the Japanese SIT market will be the launch of new sublingual immunotherapies (SLIT), by both Torii and Shionogi. Shionogi represents a new market entrant with brand power that will lead to increased awareness of SLITs in general and subsequent market growth.
- Primary research has indicated there is a number of unmet needs in the area, represented by the low drug treatment rate across all 7MM. This includes poor patient compliance, and a lack of affordable options or clinical evidence to support the use of SIT in polysensitized patients. The report highlights a number of novel R&D strategies aimed at reducing the barriers to this treatment.

View Full Report @ https://www.marketresearchreports.biz/reports/235081/opportunityanalyzer-allergic-rhinitis-allergen-specific-immunotherapy-opportunity-analysis-and-forecast-to-2018-market-research-reports

Scope

- Overview of AR, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized AR therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for seven years to 2018.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AR therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global AR therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global AR therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AR therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global AR therapeutics market from 2013-2018.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/235081

Table of Contents

1 Table of Contents 8
1.1 List of Tables 12
1.2 List of Figures 14
2 Introduction 15
2.1 Catalyst 15
2.2 Related Reports 16
2.3 Upcoming Related Reports 16
3 Disease Overview 17
3.1 Etiology and Pathophysiology 17
3.2 Classification 20
3.2.1 Seasonal and Perennial AR 20
3.2.2 ARIA Classification of AR 20
3.3 Diagnosis 21
3.4 Quality of Life 22
3.5 Symptoms 23
4 Epidemiology 24
4.1 Disease Background 24
4.2 Risk Factors and Comorbidities 25
4.2.1 Family history of allergic rhinitis is a strong predictor for allergic rhinitis in children and adults 26
4.2.2 Exposure to allergens in the environment increases the risk for allergic rhinitis 27
4.2.3 Urban living elevates the risk of allergic rhinitis 27
4.2.4 Comorbidities 28
4.3 Global and Historical Trends 29
4.3.1 US 30
4.3.2 5EU 31
4.3.3 Japan 32
4.4 Forecast Methodology 33
4.4.1 Sources Used 35
4.4.2 Sources Not Used 38
4.4.3 Forecast Assumptions and Methods 39
4.5 Epidemiological Forecast of Allergic Rhinitis (2013-2023) 43
4.5.1 Total Prevalent Cases of Allergic Rhinitis 43
4.5.2 Age-Specific Total Prevalent Cases of Allergic Rhinitis 44
4.5.3 Sex-Specific Total Prevalent Cases of Allergic Rhinitis 46
4.5.4 Age-Standardized Total Prevalence of Allergic Rhinitis 48
4.5.5 Distribution of Total Prevalent Cases of Allergic Rhinitis by Severity 49
4.5.6 Distribution of Total Prevalent Cases of Allergic Rhinitis by Type 50
4.5.7 Allergic Rhinitis Total Prevalent Cases Sensitized to Specific Allergens 51
4.6 Discussion 52
4.6.1 Epidemiological Forecast Insight 52
4.6.2 Limitations of the Analysis 53
4.6.3 Strengths of the Analysis 54
5 Competitive Assessment 55
5.1 Overview 55
5.2 Treatment Algorithm 55
5.2.1 First- and Second-Line Treatment: OTC and Prescription Antihistamines, Nasal Corticosteroids, and Minor Therapeutic Classes 57
5.2.2 Third-Line Treatment: Immunotherapy 59
5.2.3 Types of SIT Marketing Approval 64
5.3 Leading Immunotherapy Manufacturers 66
5.3.1 ALK-Abello 66
5.3.2 Stallergenes 79
5.3.3 Allergy Therapeutics 90
5.3.4 Allergopharma GmbH & Co. KG 99
5.3.5 HAL Allergy Group 106
5.3.6 Torii Pharmaceutical 111
5.4 US Market 117
5.4.1 Current Licensed US Allergen Extract Suppliers 121
6 Unmet Needs Assessment and Opportunity Analysis 124
6.1 Overview 124
6.2 Unmet Needs Analysis 126
6.2.1 Affordable Specific Immunotherapies in Countries Without Full Reimbursement 126
6.2.2 A New Generation Tablet Formulation for Every Allergen 128
6.2.3 Increased Physician Referral to Specialists for Diagnosis and Immunotherapy Initiation 130
6.2.4 Increased Compliance to SIT 133
6.2.5 Clinical Evidence for the Use of SIT in Polysensitized Patients 134
6.2.6 Standardized Allergen Extracts in Japan 135
6.3 Opportunity Analysis 136
6.3.1 A Test to Determine Lifetime Immunity to an Allergen 136
6.3.2 A Single-Dose Vaccine Course 136
6.3.3 SIT Prescribed by a Range of Specialists 137
6.3.4 Label Expansion to Prophylactically Treat Asthma and to Reduce Asthma Exacerbations 138
7 Research and Development Strategies 139
7.1 Overview 139
7.1.1 SCIT Allergen Modifications 139
7.1.2 Alternative Routes of Administration 145
7.1.3 Allergen Immunotherapy in the Treatment of Asthma 147
7.2 Clinical Trial Design 150
7.2.1 Current Clinical Trial Design 150
7.2.2 Selection of Clinically Relevant Trial Endpoints 151
7.2.3 Controlling Allergen Exposure: Environmental Exposure Chambers 154

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.